All In Biotech

Drug Trial Radar · NCT07079631

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 482 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

482

Planned (sponsor's estimate)

Start

Jul 18, 2025

Primary completion

Dec 2030

Study completion Dec 2032

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Genmab
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • BNT314Biological

    Intravenous (IV) infusion

  • PumitamigDrug

    IV infusion

  • SoC chemotherapy treatment 1Drug

    IV infusion / IV bolus

  • SoC chemotherapy treatment 2Drug

    IV infusion / IV bolus / oral

  • BevacizumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I - Part A: Occurrence of dose limiting toxicities (DLTs) during the DLT observation periodTime frame: Up to 28 days after Day 1, Cycle 1
  2. Phase I - Part A: Occurrence of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs)Time frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of investigational medicinal product (IMP)
  3. Phase I - Part A: Occurrence of dose interruption or discontinuation of study treatment due to TEAEsTime frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of IMP
  4. Phase I - Part B: Occurrence DLTs during the DLT observation period for the first five participants in each dose cohortTime frame: Up to 42 days after Day 1, Cycle 1
  5. Phase I - Part B: Occurrence of TEAEs and TRAEsTime frame: From initiation of the first dose of BNT314 + pumitamig + SoC chemotherapy until 90 days after last dose of IMP
  6. Phase I - Part B: Occurrence of dose interruption or discontinuation of study treatment due to TEAEsTime frame: From initiation of the first dose of BNT314 + pumitamig + SoC chemotherapy until 90 days after last dose of IMP
  7. Phase I - Part B: Objective response rate (ORR)Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months
  8. Phase II - Part C: Progression free survivalTime frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center

    Cleveland, Ohio · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Hämatologisch-Onkologische Praxis Eppendorf - HOPE

    Hamburg, Germany · Recruiting

  • Asklepios Tumorzentrum Hamburg

    Hamburg, Germany · Recruiting

  • National Cancer Center Hospital

    Chūōku, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Japan · Recruiting

  • Hospital HM Nou Delfos

    Barcelona, Spain · Recruiting

  • Vall D'Hebrón Hospital

    Barcelona, Spain · Recruiting

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain · Recruiting

  • Guy's & St Thomas' NHS Foundation Trust, Guy's Hospital

    London, United Kingdom · Recruiting

  • Christie NHS Foundation

    Manchester, United Kingdom · Recruiting

  • The Royal Marsden NHS

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.